Patents by Inventor Robert A. Davey
Robert A. Davey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884653Abstract: Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to series novel arylnaphthalene compounds, having a formula (I) or a pharmaceutically acceptable salt thereof, as a vacuolar-ATPase inhibitor that are useful for the treatment for a broad spectrum of viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.Type: GrantFiled: April 6, 2021Date of Patent: January 30, 2024Assignees: Purdue Research Foundation, Trustees of Boston UniversityInventors: Vincent Jo Davisson, Aaron Raymond Lindstrom, Naoaki Fujii, Robert A. Davey
-
Patent number: 11571416Abstract: Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat viral infections.Type: GrantFiled: April 13, 2018Date of Patent: February 7, 2023Assignee: Kagoshima UniversityInventors: Robert A. Davey, Yasuteru Sakurai, Masanori Baba, Norikazu Sakakibara
-
Publication number: 20210230149Abstract: Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to series novel arylnaphthalene compounds, having a formula (I) or a pharmaceutically acceptable salt thereof, as a vacuolar-ATPase inhibitor that are useful for the treatment for a broad spectrum of viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.Type: ApplicationFiled: April 6, 2021Publication date: July 29, 2021Applicant: Purdue Research FoundationInventors: Vincent Jo Davisson, Aaron Raymond Lindstrom, Naoaki Fujii, Robert A. Davey
-
Publication number: 20140378435Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Applicant: Board of Regents, University of Texas SystemInventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
-
Patent number: 8889743Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.Type: GrantFiled: December 21, 2009Date of Patent: November 18, 2014Assignee: Board of Regents, University of Texas SystemInventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
-
Publication number: 20110152344Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.Type: ApplicationFiled: December 21, 2009Publication date: June 23, 2011Inventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
-
Patent number: 7807346Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.Type: GrantFiled: May 5, 2008Date of Patent: October 5, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Robert A Davey, Andrey Kolokoltsov
-
Patent number: 7623900Abstract: A method of navigating along a biological object with a lumen represented by a three-dimensional volume data set comprises generating a plurality of navigation segments connectable in a sequence, each segment having a start point within the lumen, a direction and a length. The navigation may be used for a camera in a virtual endoscopic examination, for example. The direction of each segment is determined by casting groups of rays outwards from the start point of the segment to the object wall, and calculating an average ray length for each group. The group having the largest average ray length is selected, and the axial direction of this group is used as the direction for the segment. The average ray lengths of the groups may be weighted using the direction of the previous segments to bias the navigation generally forward, or may be weighted using a view direction of the camera to allow a user to turn the camera into a chosen branch in the object.Type: GrantFiled: September 2, 2005Date of Patent: November 24, 2009Assignee: Toshiba Medical Visualization Systems Europe, Ltd.Inventors: Alan Graham, Andrew Smout, Robert A. Davey, Laurent Lessieux
-
Publication number: 20090214663Abstract: The present invention discloses method to coat nanoparticles with viral envelope containing specific proteins. The present invention also discloses that such viral envelope coated nanoparticles can be targeted to specific cells and cellular entry pathway, thereby permitting their use as vaccines, in targeted delivery of therapeutic products and in the study of virus adsorption, cell penetration and viral entry pathways.Type: ApplicationFiled: March 26, 2009Publication date: August 27, 2009Inventors: Thomas B. Albrecht, Robert A. Davey
-
Publication number: 20080299085Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.Type: ApplicationFiled: May 5, 2008Publication date: December 4, 2008Inventors: Robert A. Davey, Andrey Kolokoltsov
-
Patent number: 7368232Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.Type: GrantFiled: January 14, 2005Date of Patent: May 6, 2008Assignee: The Board of Regents of the University of Texas SystemInventors: Robert A. Davey, Andrey Kolokoltsov
-
Patent number: 7329486Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.Type: GrantFiled: March 30, 2004Date of Patent: February 12, 2008Assignee: The Board of Regents of the University of Texas SystemInventors: Robert A. Davey, Andrey Kolokoltsov
-
Publication number: 20040191766Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.Type: ApplicationFiled: March 30, 2004Publication date: September 30, 2004Inventors: Robert A. Davey, Andrey Kolokoltsov
-
Publication number: 20020192799Abstract: The present invention provides collections of polypeptides, where each polypeptide includes a region Xaan, wherein n is from about 5 to about 21, and each Xaa is independently a random amino acid. Polynucleotides encoding the polypeptides, are also provided, as are methods for identifying a polypeptide within a collection that prevents cell death after exposure to a pathogen or a toxin, and methods for identifying a polypeptide within a collection that binds a pathogen, a toxin, a polypeptide, or a polynucleotide. The present invention also provides methods for crystallizing a polypeptide.Type: ApplicationFiled: October 15, 2001Publication date: December 19, 2002Applicant: Board of Regents, The University of Texas SystemInventors: Stanley J. Watowich, Scott C. Weaver, Robert A. Davey